Clik here to view.
The Year in Seattle Biotech: Lots of Acquisitions, Few New Startups
Luke Timmerman This was a great year for Seattle biotech if you measure success through sheer number of acquisitions. But if you prefer to measure the health of an innovation community by the number...
View ArticleClik here to view.
Oncothyreon Shares Tumble on Lung Cancer Study Speculation
Luke Timmerman Seattle-based Oncothyreon saw its shares plummet today amid speculation among investors that its experimental lung cancer vaccine isn’t going to work. Oncothyreon (NASDAQ: ONTY) shares...
View ArticleClik here to view.
Oncothyreon Grabs $47M in Stock Offering
Luke Timmerman Seattle-based Oncothyreon has raised a lot more money to run clinical trials of its experimental cancer treatments. The company (NASDAQ: ONTY) said today it has raised $47 million from...
View ArticleClik here to view.
Hard-Nosed Hedge Fund Chief Has Soft Spot for Rare-Disease Startup
Arlene Weintraub On March 19, Martin Shkreli posted an article on the investing blog Seeking Alpha urging readers to “short” shares of San Diego-based Cytori (NASDAQ: CYTX)—essentially telling them...
View ArticleClik here to view.
Oncothyreon Marches On With ‘Son of Stimuvax’ Cancer Vaccine
Luke Timmerman Many on Wall Street who follow Seattle-based Oncothyreon know it as the developer of Stimuvax, a product designed to stimulate the immune system to fight cancer cells. But what fewer...
View ArticleClik here to view.
Oncothyreon Cancer Drug Fails in Final Trial; Shares Tank
Luke Timmerman Despite all the advances of modern medicine, pharmaceutical companies still sometimes take a drug all the way to the third and final phase of clinical trials before finding out it’s a...
View ArticleClik here to view.
Third Rock’s Latest, Jounce, Grabs $47M For Cancer Immunotherapy
Luke Timmerman Scientists have been striving for decades to find a way to stimulate the immune system to fight cancer, with only a couple of recent success stories to show for it. Now Third Rock...
View ArticleClik here to view.
Ensysce’s Bet: Combining Two Risky Drug Technologies That Add Up
Bernadette Tansey At one edge of the sprawling Texas Medical Center in south central Houston, near a slew of hospitals and research hubs including the renowned MD Anderson Cancer Center, three floors...
View ArticleClik here to view.
ASCO Wrap-Up: Cancer News from the West Coast
Luke Timmerman Anybody with a more than passing interest in cancer has been transfixed the last few days by the news coming out of Chicago. The American Society of Clinical Oncology (ASCO) annual...
View ArticleClik here to view.
Oncothyreon Stock Surges on Partner’s Renewed Bet in Lung Cancer
Luke Timmerman Seattle-based Oncothyreon (NASDAQ: ONTY) was written off by a lot of investors last year when a cancer immunotherapy it developed failed in a pivotal clinical trial run by one of its...
View ArticleClik here to view.
West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More
Alex Lash [Corrected 8/14/14, 8:11pm. See below.] When Amgen (NASDAQ: AMGN) bought South San Francisco-based Onyx Pharmaceuticals last year for $10.4 billion, it expected great things from Onyx’s...
View ArticleClik here to view.
What Seattle Needs (Part 1): “Semi-Successful” Biotech Companies
Stewart Lyman I know what you’re thinking: that’s a pretty strange headline. Why would a city want to attract or build companies that are only “semi-successful?” Wouldn’t it want companies that are...
View ArticleClik here to view.
Former Dendreon CEO Gold Working on New Cancer Drug Startups
Jeff Engel Fresh off a quick exit for his latest biotech startup, former Dendreon CEO Mitch Gold has a couple of new projects up his sleeve—but he’s not letting on much yet. Xconomy caught up with...
View ArticleClik here to view.
Oncothyreon Pays $20M for Array BioPharma’s Breast Cancer Drug
Michael Davidson Oncothyreon and Array BioPharma announced today that they have updated their development agreement around a breast cancer drug invented by Array. Oncothyreon, based in Seattle, will...
View ArticleClik here to view.
West Coast Biotech Roundup: Otonomy, Oncothyreon, Gilead, & More
Life sciences news pummeled the West Coast last week like a series of storms barreling out of the North Pacific. Here’s our roundup: —Otonomy (NASDAQ OTIC), a San Diego biotech developing new...
View ArticleClik here to view.
Alpine Immune Sciences, Former Dendreon CEO’s Latest Startup, Gets $48M
Mitch Gold, the former CEO of Dendreon, has just gotten some big backing for his latest cancer drug startup. Alpine Immune Sciences, a Seattle company touting a next-gen method of harnessing our...
View ArticleClik here to view.
Bio Roundup: Fast “Cures,” Trump In Time, CRISPR In Court & More
What a week. The 21st Century Cures Act is now waiting President Obama’s promised signature after easy passage through Congress. President-elect Donald Trump re-stirred the drug-pricing pot with...
View ArticleClik here to view.
Ex-Dendreon CEO, Gold, Returns to Wall Street as Alpine, Nivalis Merge
Mitch Gold, the controversial executive who oversaw the rise of now-defunct cancer immunotherapy pioneer Dendreon, is about to head back to Wall Street. Gold’s latest startup, Seattle cancer and...
View ArticleClik here to view.
Bio Buyout Spree Continues as SeaGen Bets $614M on Cascadian Cancer Drug
In the latest in a recent spate of biopharma buyouts, Seattle Genetics has struck a deal to acquire Cascadian Therapeutics, gambling on an experimental breast cancer drug in late-stage testing. SeaGen...
View ArticleClik here to view.
Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More
The State of the Union address was…. long. At one hour and 20 minutes, President Trump fell about 9 minutes shy of the high mark. But those who stayed tuned in heard comments about several health...
View Article
